FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Abstract Full Text

Article: Coombes RC et al. A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer. N Engl J Med 2004;350(11):1081-92.

Supplementary Appendix 1

The following clinicians entered patients in the trial: T Delozier, Centre François Baclesse, Caen (96); A Veronesi, Centro di Riferimento Oncologico, Aviano (69); E Vrdoljak, Centre of Oncology, Split (65); A Monnier, Centre Hospitalier André Boulloche, Montbeliard (64); C Coombes, Charing Cross Hospital, London (63); T Nagykalnai, Uzsoki Hospital, Budapest (57); RMH Roumen, Maxima Medisch Centrum, Veldhoven (57); B Utracka-Hutka, Centre of Oncology, Gliwice (57); A Pluzanska, Medical University, Lodz (53); M Porpiglia, Ospedale Sant'Anna, Torino (52); M Steiner, R Rubinov, M Leviov, Carmel Medical Centre, Haifa (48); V Semiglazov, Prof N N Petrov, Research Institute of Oncology, St Petersburg (48); J Fox, Castle Hill Hospital, Cottingham (41); JI Mayordomo, Hospital Clinico Lozano Blesa, Zaragoza (40); J Cervek, Institute of Oncology, Ljubljana (40); HP Sleeboom, Ziekenhuis Leyenburg, The Hague (39); J Jassem, Medical University of Gdansk, Gdañsk (39); CP Hinton, Princess Royal Hospital, Telford (39); TH Paulsen, RJ Guleng, Haukeland Sykehus, Bergen (38); L Fein, Centro Oncologico de Rosario, Rosario (37); N Gutulescu, Oncological Institute, Bucharest (36); J Florián, Hospital Comarcal de Barbastro, Barbastro (36); R Rosso, National Institute for Cancer Research, Genova (34); EJ Rutgers, Antoni Van Leeuwenhoek Ziekenhuis, Amsterdam (34); M Krzakowski, Oncology Centre-Institute, Warsaw (33); Z Krajina, University Hospital, Osijek (32); H Siffnerova, Regional Hospital, Ceske Budejovice (32); M Pawlicki, M Sklodowska-Curie Memorial Cancer Institute, Krakow (32); K Drosik, Wodewodzi Osrodek Onkologii, Opole (32); M Wagnerowa, Oncology Faculty L Pasteura, Kosice (32); M Brunt, North Staffordshire Royal Infirmary, Stoke-on-Trent (31); S Vukelja, Tyler Cancer Center, Tyler (31); L Mitrowic, National Cancer Research Centre, Belgrade (31); L Cataliotti, Università degli Studi, Florence (30); H Karnicka-Mlodkowska, Maritime Hospital, Gdynia (30); H Bonnefoi, Hopital Cantonal Universitaire De Geneve, Geneva (29); G Tilch, District Hospital Rodewisch, Rodewisch (29); P Chollet, Centre Jean Perrin, Clermont-Ferrand (29); A Patel, St Margaret's Hospital, Epping (29); C Kamby, Amtssygehuset Herlev, Herlev (28); L Giustini, Ospedale Civile, Fermo (28); H Mouridsen, Rigshospitalet, Copenhagen (27); H Roche, B De Lafontan, Institut Claudius Régaud, Toulouse (27); P Tomczak, Medical University, Poznan (27); L Petruzelka, University Hospital, Prague (26); A Lortholary, Centre Paul Papin, Angers (26); MG Pacquola, Ospedale — ASL 20, Tortona (26); A Skene, Royal Bournemouth Hospital, Bournemouth (26); PF Conte, Ospedale Santa Chiara, Pisa (25); N Ghilezan, Inst Oncologic Cluj '1 Chiricuta', Cluj-Napoca (25); A Stewart, Christie Hospital, Manchester (25); M Beauduin, Cetre Hôpitalier de Jolimont-Lobbes, Haine St-Paul (24); J Andersen, Århus Kommunehospital, Århus (24); S Vassilaros, Prolipsis Diagnostic Breast Centre, Athens (24); Dr Luigi Celio, Istituto Nazionale Tumori, Milan (24); R Bastús, Hospital Mutua de Terrassa, Terrassa (24); T Marsland, Florida Oncology Association, Orange Park (24); R Paridaens, UZ Gasthuisberg, Leuven (23); V Tzekova, Queen Joanna University Hospital, Sofia (23); W Lichtenegger, University Clinic Charité, Berlin (23); H Piersma, Martini Hospital, Groningen (23); S Jones, Texas Oncology, Dallas (23); S Holmberg, Universitetssjukhuset, Möindal (22); D Verhoeven, AZ KLINA Brasschaat (21); A Hill, St Vincents University Hospital, Dublin (21); G Porcile, Ospedale San Lazzaro, Alba (21); MF Bruno, Hospital Alvarez, Buenos Aires (20); I Chernozemski, National Oncological Centre, Sofia (20); R Coleman, Weston Park Hospital, Sheffield (20); J Jadeja, Hematology/Oncology Association, Jacksonville (20); A Cohn, RMCC Colorado Springs, Colorado Springs (20); M Merlano, Ospedale S Croce, Cuneo (19); F Di Costanzo, Azienda Ospedaliera S Maria, Terni (19); A Van Bochove, Ziekenhuis de Heel, Zaandam (19); MAN Gerrits, Gooi-Noord Hospital, Blaricum (19); V Malec, Oncology Institute Rossevelta, Banska Bystrica (19); A Balil, Hospital Arnau de Vilanova, Lleida (19); C Mendiola, Hospital 12 de Octubre, Madrid (19); D Dodwell, R Knox, Harrogate District Hospital, Harrogate (19); K Horgan, D Dodwell, Leeds General Infirmary, Leeds (19); T Joannides, Singleton Hospital, Swansea (19); SJ Cawthorn, Frenchay Hospital, Bristol (19); C Ghosh, Berkshire Hematology/Oncology, Pittsfield (19); J Cantrell, Bruno Cancer Center, Birmingham (19); D Campos, Centro Médico Confidence, Buenos Aires (18); R Orti, Hospital Italiano de Buenos Aires, Buenos Aires (18); K Diedrich, Medical University Clinic, Lübeck (18); H Aas, Sykehuset i Vestfold, Tønsberg (18); A Barnadas, Hospital Germans Trias I Pujol, Barcelona (18); A Makris, Luton & Dunstable Hospital, Luton (18); T Anderson, Texas Oncology Physicians Association, Euless (18); S Chittor, Texas Cancer Center of Mesquite, Mesquite (18); J Michel, CHU de Tivoli, La Louvière (17); P Philip, Centralsygehuset Næstved, Næstved (17); P Redmond, Cork University Hospital, Cork (17); WJB Mastboom, Medisch Spectrum Twente, Enschede (17); B Nordenskjöld, Universitets sjukhuset, Linköping (17); P Simmonds, Royal South Hants Hospital, Southampton (17); R J Grieve, Walsgrave Hospital, Coventry (17); A Tomova, Regional Oncology Centre, Plodiv (16); G Piot, MD Damour, Centre Médico-Chirurgical Les Ormeaux, Le Havre (16); G Borea, Ospedale Cardarelli, Naples (15); G Ucci, Ospedale di Lecco, Lecco (16); E Einarsson, Höglandssjukhuset, Eksjö (16); S Nicholson, York District Hospital, York (16); EA Gardiol, Centro de Mastologia de Rosario, Rosario (15); J Kerger, Clinique Ste-Elizabeth, Namur (15); W Lichtenegger, Virchow Klinikum, Berlin (15); J Schlosser, Gynaecological Practice, Chemnitz (15); M Namer, Centre Antoine Lacassagne, Nice (15); G Pinotti, Ospedale di Circolo e Fondazione Macchi, Varese (15); HJT Rutten, Catharina Ziekenhuis, Eindhoven (15); H Aas, T Iversen, Sandefjord Sykehus, Sandefjord (15); A Nejim, Airedale General Hospital, Keighley (15); A Dudov, Sofia Cancer Centre, Sofia (14); P Grundtvig, Amtssygehuset Roskilde, Roskilde (14); I Lang, National Institute of Oncology, Budapest (14); B Massidda, Policlinico Universitario San Elena Monserrato, Cagliari (14); CJH Van De Velde, Leids Universitair Medisch Centrum, Leiden (14); MH Gervasio, Instituto Portugues de Oncologia, Coimbra (14); I Tengrup, L Tennvall, Universitetssjukhuset Mas, Malmö (14); A Makris, Mount Vernon Hospital, London (14); S Goodman, Yeovil Hospital, Yeovil (14); VK Modgill, Halifax General Infirmary, Halifax (14); DA Vorobiof, Sandton Oncology Centre, Johannesburg (14); E Mickiewicz, Instituto 'Angel Roffo', Buenos Aires (13); J Chirgwin, Box Hill Hospital, Melbourne (13); C Focan, Les Cliniques St-Joseph, Liège (13); N Albin, Centre d'Oncologie Médicale, Evreux (13); AA Contu, Azienda USL 1, Sassari (13); JH Svensson, Borås lasarett, Borås (13); A-C Källström, Vrinnevisjukhuset, Norrköping (13); JF Forbes, Newcastle Mater Hospital, Newcastle (12); HJ Hurtz, Practice for Internal Medicine, Haematology and Internal Oncology, Halle (12); M Tubiana-Hulin, Centre René Huguenin, Saint-Cloud (12); P Viens, Institut Paoli Calmettes, Marseilles (12); A Scanni, Ospedale Fatebenefratelli, Milan (12); E Arnoldi, Ospedale Civile, Trescore Balneario (12); A Bottini, Istituti Ospitalieri di Cremona, Cremona (12); V Muscat, S Brincat, Sir Paul Boffa Hospital, Malta (12); K Holmen, Sykehuset Levanger, Levanger (12); N Amaral, Hospital da Universidade de Coimbra, Coimbra (12); I Moreno, Hospital Municipal de Badalona, Barcelona (12); C Trask, A Robinson, Southend Hospital, Westcliff-on-Sea (12); K Mcintyre, Texas Oncology-Presbyterian, Dallas (12); A Otsuka, Rocky Mountain Cancer Center, Thornton (12); B Hohaus, District Hospital Riesa, Riesa (11); V Georgoulias, University Hospital of Crete, Crete (11); S Salvagni, Azienda Ospedaliera, Parma (11); L Bidin, Ospedale Civile, Piacenza (11); F Artioli, Ospedale B Ramazzini, Carpi (11); T Engan, KP Benedikstsson, Orkdal Sanitetsforenings Sykehus, Orkanger (11); I Campbell, Waikato Hospital, Hamilton (11); V Harvey, Auckland Hospital, Auckland (11); H Zimbler, Texas Oncology Physicians Association, Dallas (11); Z Mrsic-Krmpotic, Clinic for Tumours, Zagreb (11); JL Canon, Clinique Notre Dame et Reine Fabiola, Charleroi (10); PV Tchilingirov, Regional Oncology Centre, Stara Zagora (10); K Buser, FMH Innere Medizin Onkologie, Bern (10); A Bolanca, University Hospital 'Sestre Milosrdnice', Zagreb (10); U Reztke, Clinic of Suhl, Suhl (10); M Jouve, Institut Curie, Paris (10); G Mullins, Bon Secours Hospital, Cork (10); L Vesentini, Ospedale Sant'Anna Divisione C, Torino (10); L Gallo, Ospedale Galliera, Genova (10); I Carreca, Università degli Studi, Palermo (10); PJM Bakker, Academisch Medisch Centrum, Amsterdam (10); B Börjesson, Länssjukhuset, Halmstad (10); J Hansen, Centrallasarettet, Vasteras (10); I Koza, National Cancer Institute, Bratislava (10); A Arcusa, Hospital General de Terrassa, Barcelona (10); A Inoriza, Hospital Infanta Cristina, Badajoz (10); A Pelegri, Hospital Sant Joan, Reus-Tarragona (10); O Eremin, Lincoln and Louth County Hospital, Lincoln (10); MR Modiano, ACRC, Tucson (10); S Anthony, Cancer Care Northwest, Spokane (16); D Donat, Institute of Oncology, Sremska Kamenica (10); E Richardet, Hospital Italiano Córdoba, Córdoba (9); O Kochli, Kantonsspital Basel, Basel (9); P Zeißig, District Hospital Greiz, Greiz (9); G Gauch, Internal-oncological Practice, Gera (9); K Aabo, Viborg Sygehus, Viborg (9); P Fumoleau, Centre René Gauducheau, Nantes (9); FLG Erdkamp, Maasland Ziekenhuis, Sittard (9); L Lovén, Central sjukhuset, Kristianstad (9); P-E Jönsson, Lasarettet, Helsingborg (9); T Perren, St James' University Hospital, Leeds (9); N Stuart, Gwynedd Hospital, Bangor (9); E Galindo, South Texas Cancer Center, Mcallen (9); J Chirgwin, Maroondah Hospital, Melbourne (8); JP Salmon, Centre Hôpitalier Peltzer-La Tourelle, Verviers (8); N Dohollou, Polyclinique Nord-Aquitaine, Bordeaux (8); R Thompson, Altnagelvin General Hospital, Londonderry (8); U Folco, Ospedale Santa Corona, Pietra ligure (8); A Rosa Bian Ospedale di Thiene, Thiene (8); M Tonato, Colozza M, Policlinico Monteluce, Perugia (8); GJ Heijmans, Streekziekenhuis Midden-Twente, Hengelo (8); P Koralewski, Regional Hospital, Krakow (8); H Bång, Motala lasarett, Motala (8); A Rodriguez Lescure, Hospital General de Elche, Elche-Alicante (8); M Martin, Hospital Clinico San Carlos, Madrid (8); F Neave, North Middlesex Hospital, Edmonton (8); T Howell, Withington Hospital, Manchester (8); M Savin, North Texas Regional Cancer Center, Plano (12); D Loesch, Oncology and Hematology Assoc Inc, Indianapolis (14); A Hannois, Hospital 'Eva Perón', Buenos Aires (7); A Mohr, Practice for Hematology and Oncology, Hamburg (7); T Laube, Henneberg-Kliniken, Hildburghausen (7); S Omar, National Cancer Institute, Cairo (7); J Bonneterre V. Servent, Centre Oscar Lambret, Lille (7); S Danese, Ospedale Sant'Anna Divisione A, Torino (7); MR Sertoli, National Institute for Cancer Research, Genova (7); RMJM Butzelaar, St Lucas Hospital, Amsterdam (7); H Gomez, Inst de Enfermedades Neoplásicas, Lima (7); P Skoog, Sjukhuset I Varnamo, Varnamo (7); I Alvarez, Hospital de Donostia, San Sebastian (7); E Aranda, Hospital Provincial Reina Sofia, Cordoba (7); J Lizón, Hospital Universitari Sant Joan D'Alcant, Alicante (7); HMA Yosef, Hairmyers Hospital, East Kilbride (7); P Barrett-Lee, Velindre Hospital, Cardiff (7); AU Buzdar, UT MD Anderson Cancer Center, Houston (7); T George, West Texas Cancer Center, Odessa (7); J Olivaires, Texas Oncology Physicians Association, Garland (7); A Otsuka, RMCC Lakewood, Lakewood (7); M Vsianska, Masaryka's Oncology Institute, Brno (6); U Köhler, Town Hospital St Georg, Leipzig (6); B Lindeløv, Vejle Sygehus, Vejle (6); DB Toftdahl, Centralsygehuset Hillerød, Hillerød (6); C Veyret, Centre Henri Becquerel, Rouen (6); D Castera, Centre d'Imagerie et d'Oncologie, Perpignan (6); P Kerbrat, Centre Eugène Marquis, Rennes (6); P Vassipoulos, St Savvas Anticancer Institute, Athens (6); W Yeo, Prince of Wales Hospital, Hong Kong (6); C Boni, Arcispedale 'S Maria Nuova', Reggio Emilia (6); E Aitini, Azienda Ospedaliera Civile Carlo Poma, Mantova (6); G Luporini, Ospedale San Carlo Borromeo, Milan (6); MG Herben, Medisch Centrum Haaglanden, Leidenschendam (6); H Espelid, JHH Sen, Haugesund sjukenhus, Haugesund (6); S Dahl, Molde sjukehus, Molde (6); C Ingvar, Universitessjukhuset, Lund (6); A Meana, Hospital Universitario de Alicante, Alicante (6); RK Agrawal, Royal Shrewsbury Hospital, Shrewsbury (6); D Gruenberg, Northwest Cancer Specialists, Portland (6); A Nunez de Pierro, Hospital Fernandez, Buenos Aires (5); G Gill, Royal Adelaide Hospital, Adelaide (5); J M Nogaret, Institut Jules Bordet, Bruxelles (5); B Honhon, Hôpital St-Joseph, Gilly (5); H Wassenaar, AZ Jan Palfijn, Merksem (5); Ph Warnier, Clinique Europe St-Michel, Bruxelles (5); C Sessa, Ospedale San Giovanni, Bellinzona (5); P Padrik, Tartu University Clinic, Tartu (5); JP Guastalla, Centre Léon Bérard, Lyon (5); D Serin, Clinique Sainte-Catherine, Avignon (5); D Jaubert, Clinique Tivoli, Bordeaux (5); M Dank, Semmelweis Medical University, Budapest (5); FH Given, University College Hospital, Newcastle (5); V Mascia, E De Fraia, Ospedale Oncologico 'A Businco', Cagliari (5); V Silingardi, Cattedra Oncologia Medica, Modena (5); R Labianca, Ospedali Riuniti di Bergamo, Bergamo (5); A Bagnulo, Ospedale San Sebastiano di Correggio, Correggio (5); G Gardani, Ospedale San Gerardo, Monza (5); J Wils, GS Liem St Laurentius Ziekenhuis, Roermond (5); JKS Nuytinck, Amphia ziekenhuis, location Galderseweg, Breda (5); E Formoe, Sykehuset Østfold, Fredrikstad (5); T Ambré, Central lasarettet, Växjö (5); J Alés, Hospital Ruber Internacional, Madrid (5); J Mansi, St George's Hospital, London (5); J Graham, Taunton & Somerset NHS Trust, Taunton (5); J Joffe, J Sainsbury, Huddersfield Royal Infirmary, Huddersfield (5); J Stone, North Florida Hematology/Oncology Association, Jacksonville (5); RH Good, Texoma Cancer Center, Sherman (5); T Cartwright, Ocala Oncology Center, Ocala (5); ID Werner, Groote Schuur Hospital, Cape Town (5); J Beith, Royal Prince Alfred Hospital, Sydney (4); FJ Tigges, Oncological Practice, Munich (4); E Sandberg, Centralsygehuset Esbjerg, Esbjerg (4); JP Lotz, Hôpital Tenon, Paris (4); D Carney, T Gorey, Mater Misericordiae Hospital, Dublin (4); J Shapira, A Neumann, Meir Hopital, Kfar Saba (4); A Goldhirsch, Instituto Europeo di Oncologia, Milan (4); M Dicato, Centre Hospitalier de Luxembourg, Luxembourg (4); H de Graaf, Medisch Centrum Leeuwarden Zuid, Leeuwarden (4); E Maartense, Reiner de Graaf Gasthuis, Delft (4); J Burghouts, Bosch Medicentrum - Groot Zeikenhuis, Hertogenbosch (4); G Tejler, Kirurgiska Kliniken, Vastervik (4); J Cassinello, Hospital General de Guadalajara, Guadalajara (4); A Jones, Royal Free Hospital, London (4); C Gaffney, Royal Gwent Hospital, Newport (4); R Blum, E Abdi, Bendigo Hospital, Bendigo (3); D Becquart, AZ Middleheim, Antwerpen (3); L Dirix, AZ St-Augustinus, Wilrijk (3); J Janssens, Salvatorziekenhuis, Hasselt (3); J Janssens, Ziekenhuis Oost Limburg, Genk (3); N Marschner, Practice For Internal Medicine & Haematology, Freiburg (3); B Blaska-Jaulerry, Centre Hospitalier de Lagny/Marne La Vallée, Lagny/marne (3); G Prevot, Centre Hospitalier du Hasenrain, Mulhouse (3); L Mirah Lev, Bnai-Zion Medical Centre, Haifa (3); A Shani, NB Baruch, Kaplan Hospital, Rehvot (3); T Peretz, M Gips, Hadassah University Hospital, Jersualem (3); F Cognetti, Polo Oncologico Romano, Rome (3); JWR Nortier, Diakonessenhuis, Utrecht (3); JGJ Roussel, Ziekenhuis Centrum Apeldoorn, Apeldoorn (3); K Unneberg, Rjukan Sykehus, Rjukan (3); T Nestvold, EA Bringeland, Nordland Sentralsykehus, Bodø (3); R Fogelkvist, Notodden Sykehus, Notodden (3); J Due, S Muller, Universitetssykehuset i Nord-Norge, Tromsø (3); D Gilligan, Hinchingbrooke Hospital, Huntingdon (3); J McAleer, Belfast City Hospital, Belfast (3); C Yiangou, Queen Alexandra Hospital, Portsmouth (3); L Foote, Texas Oncology PA, Houston (3); M Schottstaedt, Longview Cancer Center, Longview (3); FA Holmes, Texas Oncology, Houston (3); J Cantrell, Birmingham Hematology and Oncology Assoc, Birmingham (3); R Wainstein, Hospital Prof 'Dr Alejandro Posadas', Buenos Aires (2); O Contreras Ortiz, University Hospital 'Jose de San Martin', Buenos Aires (2); J Martinez, Hospital Britanico, Buenos Aires (2); S Della-Fiorentina, Liverpool Hospital, Liverpool (2); S Beslija, University Clinical Centre in Sarajevo, Sarajevo (2); JB Vermorken, Universitair Ziekenhuis Antwerpen, Edegem (2); M Thirion, Centre Hôpitalier Ambroise Paré, Mons (2); J Fraikin, Clinique Louis Caty, Baudour (2); M Castiglione, Inselspital, Bern (2); W Jäger, University Clinic, Erlangen (2); H Fabriz, Clinic of Weiden, Weiden (2); K Neis, Caritasklinik St Theresia, Saarbrücken (2); JP Labat, CHU de Brest, Brest (2); O Dupuis, Centre Jean Bernard, Le Mans (2); J Datchary, Centre Hospitalier Annecy, Annecy (2); P Allain, Centre Maurice Tubania, Caen (2); M Clerico, Ospedale degli Infermi, Biella (2); M Lopez, Polo Oncologico Romano, Rome (2); G Nalli, Ospedale Maggiore, Lodi (2); R Aspevik, Rana Sykehus, Selfors (2); A Fràguas, Hospital de Espirito Santo, Evora (2); S Curescu, Municipal Kospital, Medical Oncology Department, Timisoara (2); JM Cuevas, Hospital Virgen de los Lirios, Alcoy-Alicante (2); C Bradley, Bradford Royal Infirmary, Bradford (2); R Kapoor, Texas Oncology Physicians Association, San Antonio (2); S Akbain, Texas Oncology Physicians Association, Arlington (2); MK Croghan, Arizona Oncology Association, Washington (2); M Modiano, Hematology and Oncology, Tucson (2); R Taetle, Hematology oncology Association, Tucson (2); J Beith, Dubbo Base Hospital, Dubbo (1); P Gobert, Clinique St-Joseph, Arlon (1); H Bondue, Institut Médical Edith Cavell, Bruxelles (1); R Böhm, Town Hospital Martha Maria, Halle (1); KA Møller, Centralsygehuset Herning, Herning (1); JP Brette, Hôpital Civil, Strasbourg (1); G Netter Pinon, Centre Hospitalier de Meaux, Meaux (1); L Grogan, Beaumont Hospital, Dublin (1); B Klein, E Sadikov, Rabin Medical Centre Campus Golda, Petah-Tikva (1); M Botta, Ospedale Civile Santo Spirito, Casale Monferrato (1); S Barni, Azienda Ospedaliera di Treviglio, Treviglio (1); I Van Meerwijk, Ziekenhuis Eemland, Amersfoort (1); R Kåresen, Ullevål Sykehus, Oslo (1); J Godes, Hospital General de Valencia, Valencia (1); A Aramburo, Hospital General de Albacete, Albacete (1); A Jones, Whittington Hospital, London (1); B Zanger, Memorial Southwest Hospital, Houston (1); JT Fleagle, Rocky Mountain Cancer Center, Boulder (1); A Greenspan, Oncology/Hematology Assoc, Indianapolis (1); R Marschke, Rocky Mountain Cancer Center, Fort Collins (1); L Garbo, Capital District Hematology, Latham (1).

We are grateful to the members of the Independent Data Monitoring Committee: Dr K Prithcard, Toronto Sunnybrook Regional Cancer Center, Toronto; Dr M Buyse, The International Drug Development Institute, Belgium; Professor S Kvinnsland, Haukeland University Hospital, Bergen, Norway.

We are grateful to the following people who helped with the study: Elizabeth Coles, Alistair Meneely, Sarah Fancy, Kathryn Wright, Lynda Micklewright, Iva Amoako, Lynne Booth, Graeme Kerson, Samiya Chaudhry, Rekha Patel, Marie Miller and Hannah McLauchlin of the CDC; María Alejandra Diaz, Argentine Breast Cancer Group, Argentina; Leah Rutkay, Karen Hancock, Dianne Lidsay and Amanda McCue, ANZ Breast Cancer Trials Group, Australia; Marzena Lubiejewska, Grazyna Koperska, Julian Stec and Katarzyna Malinowska, Central and Eastern European Oncology Group, Poland; Annie Jespersen and Suzanne Moeller, Danish Breast Cancer Cooperative Group, Denmark; Irene Van Hoorebeeck and Patrick Therasse, European Organisation for Research and Treatment of Cancer, Brussels; Rosa Gonzalezgalindo and Jorge Curto, Grupo Espanol de Investigacion del Cancer de Mama, Spain; Dr Rita Lionetto and Alessandra Zanotta, Gruppo Oncologico Nord Ovest, Italy; Roberta Camisa, Gruppo Oncologico Italiano di Ricerca sul Cancro, Italy; Helen Mueller and Anna Saurer International Breast Cancer Study Group, Switzerland; Marie Emson, Sarah Stramick and Navdip Sahota, International Collaborative Cancer Group, England; Stella Nivy, Israeli Clinical Oncology Group, Israel; Katya Mantoan, Italian Trials in Medical Oncology, Italy; David Ryder, North West England, England; Randi Eikeland, Norwegian Breast Cancer Group, Norway; Claire Harman, Emma Townsend and Stephanie Pollard, Yorkshire Breast Group, England; Mylene Mahouy and Dr Michel Henry-Amar, Federation Nationale des Centres de Lutte Contre le Cancer, France; Kerstin Baer, German Adjuvant Exemestane Group, Germany; Lucy Branston and Jeannie Bishop, Wales Cancer Trials Network, Wales; Erin Fenske, Candace Branam, Jennifer Davis, and Nori Sullivan, U.S. Oncology, USA.

Abstract Full Text